Phase 1 — Agitation
Reassess pain, hypoxemia, withdrawal, sepsis, urinary retention, sleep disruption and delirium drivers before adding medication. Antipsychotics do not correct the underlying cause of ICU delirium.
A complication-first bedside problem for an ICU patient exposed to antipsychotics who develops worsening agitation, rigidity, hyperthermia or electrical instability.
The clinical task is to avoid reflexively escalating antipsychotics when the patient is deteriorating. Reconstruct medication exposure and timing, reassess the cause of agitation, review temperature and neuromuscular findings, and inspect the ECG/QTc and electrolytes.
Reassess pain, hypoxemia, withdrawal, sepsis, urinary retention, sleep disruption and delirium drivers before adding medication. Antipsychotics do not correct the underlying cause of ICU delirium.
Stop potentially causative dopamine-blocking drugs and evaluate for NMS while considering serotonin syndrome, malignant hyperthermia, severe infection, withdrawal and other hyperthermic syndromes.
Review QT-prolonging co-medications, potassium and magnesium; correct reversible risk factors and avoid further QT-prolonging exposure when risk is clinically important.
Evidence status
Review metadata not yet recorded.
Status, review dates and guideline versions appear here once editorial metadata is authored for this content.
Bedside trajectory assessment, respiratory mechanics, bulbar function, airway timing, and disease-specific immunotherapy in acute neuromuscular crisis.
From 'analgesia-first' multimodal pain control and light sedation targeting to daily SAT/SBT coordination, delirium screening, and early mobility.
From acute GCS drop and herniation emergency measures to emergent CT, neurocritical intervention, and death by neurologic criteria determination.
From securing the basics to categorizing structural, toxic-metabolic, infectious, and seizure-related causes.
Safe ICU use of antipsychotics: delirium evidence, agitation control, QTc/torsades risk, NMS, EPS, interactions, and deprescribing.
Bedside differentiation and ICU management of serotonin toxicity versus neuroleptic malignant syndrome.
Analgesia-first sedation, light sedation targets, ABCDEF bundle, spontaneous breathing trials, and non-pharmacologic delirium mitigation.